Log in to your Inderes Free account to see all free content on this page.
Scibase Holding
0.3 SEK 0%35 investors are following this company
SciBase Holding is a medical technology company. The Group specializes in the management of cancer diagnostics, mainly focused on the treatment and detection of various melanomas. The company has developed an electric handheld probe that analyzes the measurement signal to detect specific changes in the body's skin tissue. The head office is located in Stockholm.
P/E (24e)
-1.24
EV/EBIT (adj.) (24e)
-0.98
P/B (24e)
2.32
Dividend yield-% (24e)
-
Target price
0.35 SEK
Recommendation
Reduce
Updated
18.4.2024
First North Stockholm
SCIB
Daily low / high price
0.3 / 0.3
SEK
Market cap
42.48M SEK
Turnover
2.89K SEK
Volume
9.6K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Luiro
Head of Nordic ER Development, Analyst
Financial calendar
Extraordinary general meeting
13.05.2024
Interim report
31.05.2024
General meeting
13.06.2024
Interim report
21.08.2024
Interim report
12.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Gell Group | 11.0 % | 11.0 % |
Avanza Pension | 9.7 % | 9.7 % |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 9.5 | 11.7 | 17.9 | 23.2 | 31.9 | 50.4 | 81.5 | 129.3 |
growth-% | 2.6 % | 23.2 % | 52.6 % | 29.9 % | 37.3 % | 57.9 % | 61.6 % | 58.7 % |
EBITDA | -32.2 | -38.7 | -42.8 | -50.6 | -52.7 | -44.0 | -26.3 | 3.0 |
EBIT (adj.) | -34.8 | -41.6 | -46.4 | -53.9 | -56.1 | -46.9 | -29.5 | -0.4 |
EBIT | -34.8 | -41.6 | -46.4 | -53.9 | -56.1 | -46.9 | -29.5 | -0.4 |
Profit before taxes | -35.0 | -41.8 | -43.2 | -55.6 | -56.7 | -47.4 | -30.0 | -0.9 |
Net income | -35.0 | -41.8 | -43.2 | -55.6 | -56.7 | -47.4 | -30.0 | -0.9 |
EPS (adj.) | -1.12 | -0.67 | -0.63 | -0.51 | -0.24 | -0.20 | -0.13 | -0.00 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Login required
This content is only available for logged in users
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -337.7 % | -329.6 % | -239.1 % | -217.5 % | -165.0 % | -87.2 % | -32.3 % | 2.4 % |
EBIT-% (adj.) | -365.2 % | -354.8 % | -259.5 % | -232.0 % | -175.9 % | -93.1 % | -36.2 % | -0.3 % |
EBIT-% | -365.2 % | -354.8 % | -259.5 % | -232.0 % | -175.9 % | -93.1 % | -36.2 % | -0.3 % |
ROE | -88.7 % | -71.0 % | -89.9 % | -162.8 % | -154.9 % | -736.9 % | 92.9 % | 1.9 % |
ROI | -88.2 % | -70.7 % | -96.7 % | -158.0 % | -153.4 % | -151.8 % | -73.4 % | -0.7 % |
Login required
This content is only available for logged in users
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (SEK) | 4.48 | 5.36 | 3.71 | 0.83 | 0.30 | 0.30 | 0.30 | 0.30 |
Shares | 54.8 | 68.5 | 68.5 | 119.8 | 233.7 | 233.7 | 233.7 | 233.7 |
Market cap | 245.6 | 366.9 | 253.9 | 99.9 | 70.1 | 70.1 | 70.1 | 70.1 |
Enterprise value | 204.2 | 301.3 | 235.1 | 65.8 | 55.1 | 109.0 | 149.8 | 167.5 |
EV/S | 21.4 | 25.7 | 13.1 | 2.8 | 1.7 | 2.2 | 1.8 | 1.3 |
EV/EBITDA | - | - | - | - | - | - | - | 55.1 |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 5.2 | 5.2 | 10.1 | 2.3 | 2.3 | - | - | - |
P/S | 25.8 | 31.3 | 14.2 | 4.3 | 2.2 | 1.4 | 0.9 | 0.5 |
Dividend yield | ||||||||
Equity ratio | 79.1 % | 82.8 % | 50.6 % | 66.9 % | 51.7 % | -24.3 % | -44.7 % | -30.7 % |
Gearing ratio | -88.4 % | -92.7 % | -74.6 % | -79.2 % | -49.7 % | -225.1 % | -168.5 % | -202.1 % |
Login required
This content is only available for logged in users
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 5.1 | 5.1 | 7.2 | 5.8 | 23.2 | 6.8 | 7.3 | 9.8 | 8.1 |
EBITDA | -10.0 | -12.8 | -12.0 | -15.7 | -50.6 | -12.8 | -13.2 | -12.7 | -14.0 |
EBIT | -10.8 | -13.8 | -12.7 | -16.6 | -53.9 | -13.7 | -14.1 | -13.6 | -14.8 |
Profit before taxes | -10.9 | -11.4 | -12.8 | -20.5 | -55.6 | -13.8 | -14.2 | -13.7 | -15.0 |
Net income | -10.9 | -11.4 | -12.8 | -20.5 | -55.6 | -13.8 | -14.2 | -13.7 | -15.0 |
Login required
This content is only available for logged in users
ShowingAll content types
SciBase announces outcome in rights issue of units
Last day of trading in unit rights in SciBase rights issue
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio